Five people have been charged for allegedly participating in an insider trading scheme tied to Novartis’ $3.2 billion acquisition of Chinook, including a former director of the biotech’s board.

Sanofi’s sponsorship of the Olympics and Paralympics has led to a breach of the U.K. marketing code. Self-regulatory body the PMCPA ruled that the company brought discredit on the pharma industry by giving 21 tickets to the games, worth a combined 2,190 euros ($2,488), to patients in the U.K.

Eli Lilly is expanding its efforts to advance next-generation pain medications. The Big Pharma has sealed a deal to acquire SiteOne Therapeutics, primarily for a non-opioid pain asset ready to enter phase 2 trials.

With the goal to become a top 3 pharma company in China, Novartis has been busy tapping into the expertise of local drugmakers. In its latest collaboration, Novartis has signed a strategic agreement with Shanghai Pharma to help sell some ophthalmic products in the country.

As it works to send opioid use disorder treatment Sublocade back into its prior growth territory, Indivior is switching up its commercial team.

The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.

The FDA has slapped Savara with a refuse to file letter after the biotech in March applied for approval of its inhaled respiratory disease candidate molgramostim in autoimmune pulmonary alveolar proteinosis.

The layoffs at Allergan's Irvine, California, headquarters are effective on July 22, according to a recent filing with the state.